The most credible disease-modifying model is that trazodone must reach a higher exposure range, likely around 150-200 mg/day, to engage the PERK-eIF2alpha integrated stress response in neurons and restore translation. This remains a mechanistically grounded but unvalidated human threshold derived mainly from preclinical tauopathy/prion data and supported by the observation that many real-world dementia prescriptions were likely below this range.
Curated pathway from expert analysis
flowchart TD
A["Target Gene: EIF2AK3 EIF2S1 ATF4 DDIT3"]
B["Molecular Mechanism<br/>Pathway Activation"]
C["Cellular Phenotype<br/>Neuronal / Glial Response"]
D["Network Effect<br/>Circuit-Level Consequence"]
E["Disease Relevance<br/>Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for EIF2AK3; yet. Search RCSB →
Median TPM across 13 brain regions for EIF2AK3; EIF2S1; ATF4; DDIT3 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for EIF2AK3; EIF2S1; ATF4; DDIT3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with Alzheimer's disease are randomized to receive trazodone 150–200 mg/day for 12 weeks THEN a measurable reduction in cerebrospinal fluid phosphorylated eIF2α (p‑eIF2α) levels will be ob | CSF p‑eIF2α concentration decreases by ≥20 % (or falls below the assay’s lower limit of quantification) in the high‑dose group relative to the low‑dose group af | — no observation — | pending | 0.55 |
| IF individuals with prodromal or mild dementia are treated with trazodone 150–200 mg/day for 12 months THEN their annual decline in global cognition (as measured by change in MMSE score) will be at le | High‑dose trazodone group shows an average MMSE decline of ≤2 points over 12 months, whereas the low‑dose group declines ≥4 points. | — no observation — | pending | 0.50 |